Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (101-110 of 204) with videos related to

Pageof 21
Sort By:
Annals of the American Thoracic Society|August 29, 2014
Open-access biorepository for idiopathic pulmonary fibrosis. The way forwardEric S White, Kevin K Brown, Harold R Collard, et al.
The European Respiratory Journal|August 25, 2018
Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosisStephen M Humphries, Jeffrey J Swigris, Kevin K Brown, et al.
The European Respiratory Journal|March 12, 2016
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosisGanesh Raghu, Mary Beth Scholand, João de Andrade, et al.
Radiology|May 12, 2017
Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-upStephen M Humphries, Kunihiro Yagihashi, Jason Huckleberry, et al.
The Lancet. Respiratory Medicine|April 20, 2015
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trialsMichael T Durheim, Harold R Collard, Rhonda S Roberts, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
The European Respiratory Journal|August 30, 2022
Nintedanib in children and adolescents with fibrosing interstitial lung diseasesRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
BMJ Open Respiratory Research|July 7, 2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO RegistryLaurie D Snyder, Christopher Mosher, Colin H Holtze, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
Pageof 21

Showing results (101-110 of 204) with videos related to

Sort By:
Pageof 21
Annals of the American Thoracic Society|August 29, 2014
Open-access biorepository for idiopathic pulmonary fibrosis. The way forwardEric S White, Kevin K Brown, Harold R Collard, et al.
The European Respiratory Journal|August 25, 2018
Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosisStephen M Humphries, Jeffrey J Swigris, Kevin K Brown, et al.
The European Respiratory Journal|March 12, 2016
FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosisGanesh Raghu, Mary Beth Scholand, João de Andrade, et al.
Radiology|May 12, 2017
Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-upStephen M Humphries, Kunihiro Yagihashi, Jason Huckleberry, et al.
The Lancet. Respiratory Medicine|April 20, 2015
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trialsMichael T Durheim, Harold R Collard, Rhonda S Roberts, et al.
Respiratory Medicine|January 23, 2019
Lung function outcomes in the INPULSIS<sup>®</sup> trials of nintedanib in idiopathic pulmonary fibrosisKevin K Brown, Kevin R Flaherty, Vincent Cottin, et al.
The European Respiratory Journal|August 30, 2022
Nintedanib in children and adolescents with fibrosing interstitial lung diseasesRobin Deterding, Lisa R Young, Emily M DeBoer, et al.
American Journal of Respiratory and Critical Care Medicine|January 20, 2022
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)Fernando J Martinez, Marlies S Wijsenbeek, Ganesh Raghu, et al.
BMJ Open Respiratory Research|July 7, 2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO RegistryLaurie D Snyder, Christopher Mosher, Colin H Holtze, et al.
The Lancet. Respiratory Medicine|March 9, 2020
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U Wells, Kevin R Flaherty, Kevin K Brown, et al.
Pageof 21